Nature Communications (Jan 2019)
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
- Stefano Annunziato,
- Julian R. de Ruiter,
- Linda Henneman,
- Chiara S. Brambillasca,
- Catrin Lutz,
- François Vaillant,
- Federica Ferrante,
- Anne Paulien Drenth,
- Eline van der Burg,
- Bjørn Siteur,
- Bas van Gerwen,
- Roebi de Bruijn,
- Martine H. van Miltenburg,
- Ivo J. Huijbers,
- Marieke van de Ven,
- Jane E. Visvader,
- Geoffrey J. Lindeman,
- Lodewyk F. A. Wessels,
- Jos Jonkers
Affiliations
- Stefano Annunziato
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Julian R. de Ruiter
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Linda Henneman
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Chiara S. Brambillasca
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Catrin Lutz
- Division of Molecular Pathology, The Netherlands Cancer Institute
- François Vaillant
- ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research
- Federica Ferrante
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Anne Paulien Drenth
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Eline van der Burg
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Bjørn Siteur
- Preclinical Intervention Unit, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute
- Bas van Gerwen
- Preclinical Intervention Unit, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute
- Roebi de Bruijn
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Martine H. van Miltenburg
- Division of Molecular Pathology, The Netherlands Cancer Institute
- Ivo J. Huijbers
- Transgenic Core Facility, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute
- Marieke van de Ven
- Preclinical Intervention Unit, Mouse Clinic for Cancer and Aging (MCCA), The Netherlands Cancer Institute
- Jane E. Visvader
- ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research
- Geoffrey J. Lindeman
- ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research
- Lodewyk F. A. Wessels
- Cancer Genomics Netherlands, The Netherlands Cancer Institute
- Jos Jonkers
- Division of Molecular Pathology, The Netherlands Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-019-08301-2
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 12
Abstract
It is difficult to identify cancer driver genes in cancers, for instance BRCA1 mutated breast cancer, that are characterised by large scale genomic alterations. Here, the authors develop genetically engineered mouse models of BRCA1-deficient breast cancer that allow highthroughput in vivo perturbation of candidate driver genes, validating drivers Myc, Met, Pten and Rb1, and identifying MCL1 as a collaborating driver whose targeting can impact efficacy of PARP inhibition.
